Aptahem AB (publ), a biotechnology company, engages in the development of ribonucleic acid-based pharmaceuticals in Sweden. The company’s lead product candidate is Apta-1, which is in Phase I clinical trial for the treatment of patients with sepsis/septic shock and severe inflammatory conditions, as well as to prevent organ and tissue damages in life-threatening conditions. It also develops Apta-2 which is in preclinical stage for the treatment of inflammation; and Apta-3 which is in discovery stage. The company has a collaboration with Hongene Biotech for the manufacturing of RNA and oligonucleotides. Aptahem AB (publ) was incorporated in 2014 and is based in Malmö, Sweden.
तुलना करने के लिए मीट्रिक्स | APTA | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधAPTAपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −2.9x | −3.1x | −0.4x | |
PEG अनुपात | −0.04 | −0.07 | 0.00 | |
क़ीमत/बुक | 0.3x | 3.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 7.3x | 14.4x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 121.5% | 58.6% | |
उचित मूल्य अपसाइड | अनलॉक करें | 23.1% | 8.2% | अनलॉक करें |